Radioligand therapy (RLT) used to treat cardiac metastasis of pancreatic neuroendocrine tumor.

放射性配体疗法 （ RLT ） 用于治疗胰腺神经内分泌肿瘤的心脏转移。

• 发表时间: 2024 Mar
• 来源期刊: Clin Case Rep
• DOI: 10.1002/ccr3.8622
• PMID: 38449894
• 文章类型: Case Reports
• 作者列表: Ved KJ,Bhatt A,Burke AM,Larkins MC,Pandya D,Marcu CB

关键词: Lutathera; cardiac metastases; neuroendocrine neoplasms (NENs); peptide receptor radiotherapy (PRRT); somatostatin receptor

Abstract

Radioligand Therapy (RLT) in the form of [177Lu] Lu-DOTA-TATE (Lutathera®) is a promising treatment for pancreatic neuroendocrine tumors (pNETs) with cardiac metastasis. We present a patient treated with [177Lu] Lu-DOTA-TATE that showed shrinkage of metastasis after four treatments at 7.4 GBq every 8 weeks.

摘要

[177Lu]Lu-DOTA-TATE（Lutathera®）形式的放射性配体疗法（RLT）是一种有希望的治疗胰腺神经内分泌肿瘤（pNET）心脏转移的方法。我们介绍了接受[177Lu]Lu-DOTA-TATE治疗的患者，该患者在每8周以7.4GBq进行四次治疗后显示出转移减少。